FDA approves Skyrizi for adults with active psoriatic arthritis

摘要

The FDA has approved Abb Vie s Skyrizi for the treatment of adults with active psoriatic arthritis, expanding its initial indication from plaque psoriasis only. Skyrizi (risankizumab-rzaa, AbbVie/ Boehringer Ingelheim), an interleukin-23 inhibitor, made its U.S. debut in 2019 for moderate to severe plaque psoriasis (PsA) among adults who are candidates for systemic therapy or phototherapy. The new approval for PsA follows results from the KEEPsAKE 1 and KEEPsAKE 2 trials, both of which resulted in statistically greater improvements in signs and symptoms, relative to placebo, among patients who received the drug.